Zeskind Benjamin J. 4
4 · Immuneering Corp · Filed Feb 17, 2023
Insider Transaction Report
Form 4
Immuneering CorpIMRX
Zeskind Benjamin J.
DirectorPRESIDENT AND CEO
Transactions
- Award
Stock Option
2023-02-15+352,244→ 352,244 totalExercise: $4.25Exp: 2033-02-15→ Class A Common Stock (352,244 underlying) - Award
Stock Option
2023-02-15+21,756→ 374,000 totalExercise: $4.68Exp: 2028-02-15→ Class A Common Stock (21,756 underlying)
Footnotes (2)
- [F1]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027.
- [F2]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027.